View

The Study

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

In simple terms

This study watched what happened when 127 people took a new medicine, but it didn't compare them to others who didn't take it or use chance to decide who got it. So we can say what happened to these people, but we can't say the medicine caused the improvements — it might just be luck or other factors.

38%

Analysis score

38/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting0
Methodology12
Publication100
Statistical54
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

A new pill called RMC-6236 was tested in patients with advanced pancreatic cancer who had already tried other treatments.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
38

38 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1This is promising because most patients with this cancer survive only 6–7 months with standard treatment, but here, half lived over 14 months and many had cancer DNA vanish from blood.
  2. 2In 56 patients with KRAS G12X mutation, 95% had over half their cancer DNA in blood disappear, and half had all detectable cancer DNA vanish.
  3. 3The pill helped 29% of patients' tumors shrink.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Journal of Clinical Oncology

Year

2025

Authors

I. Garrido-Laguna, B. Wolpin, Wungki Park, Nilofer S. Azad, A. Spira, Alexander N Starodub, D. Sommerhalder, Salman R. Punekar, B. Herzberg, M. Barve, Meredith S. Pelster, Jennifer B. Valerin, J. R. Hecht, Rashmi Vora, A. Hegde, Clay Gustafson, Lin Tao, S. Kar, Kevin K. Lin, D. Hong

28 citations
Analysis v5
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.